Hilhorst M.
- Country
- The Netherlands
- Department
- Division of Internal Medicine
Research Overview
- A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy
- Efficacy and Safety Evaluation of Frexalimab, SAR442970, and Rilzabrutinib in Primary Focal Segmental Glomerulosclerosis and Minimal Change Disease
- Evaluation of Mezagitamab (TAK-079) Efficacy and Safety in Adults with Primary IgA Nephropathy: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 31 of 118 partner sites.
Specializations
Nephrology & Glomerular Disorders
The investigator specializes in the treatment of primary focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD), focusing on innovative therapeutic approaches for these rare kidney conditions.
- Glomerular Disease Management
- Proteinuria Treatment
- Renal Function Preservation
Key interests include interventional treatments for glomerular disorders affecting patients across different age groups.
Immunology
With expertise in immune system diseases, the investigator explores novel therapeutic agents targeting immune-mediated kidney disorders and their underlying mechanisms.
- Autoimmune Kidney Diseases
- Immunological Interventions
- Novel Therapeutic Approaches
The focus extends to understanding immune system involvement in renal pathologies.
Therapeutic Innovation
The investigator evaluates targeted therapeutic agents for kidney diseases, including novel compounds for treating glomerular disorders.
- Emerging Therapies
- Disease-Modifying Treatments
- Clinical Efficacy Assessment
Areas of interest include development of treatments for rare kidney disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.